Galectin-3 expression was statistically significantly higher among type two diabetics with CAD than type two diabetics with no CAD than the control group (3.3±2.5 > 1.99±0.8 > 1.06±0.7, p-value 0.001**), the highest (CC genotype) percentage was among type 2 diabetes with CAD (62.5% versus 35.0% and 2.5%) of type two diabetes with no CAD and control groups, respectively. This evidence concerns the gene LGALS3 and coronary artery disorder.